ResMed Inc. (ASX:RMD)

Theseus Pharmaceuticals Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 63.68 billion. The enterprise value is 63.13 billion.

Market Cap	63.68B
Enterprise Value	63.13B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	May 7, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.14%
Shares Change (QoQ)	-0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.49M

Valuation Ratios

The trailing PE ratio is 29.81 and the forward PE ratio is 25.95.

PE Ratio	29.81
Forward PE	25.95
PS Ratio	8.11
PB Ratio	7.00
P/TBV Ratio	17.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.35, with an EV/FCF ratio of 24.91.

EV / Earnings	29.55
EV / Sales	8.01
EV / EBITDA	21.35
EV / EBIT	24.37
EV / FCF	24.91

Financial Position

The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.14.

Current Ratio	3.44
Quick Ratio	2.11
Debt / Equity	0.14
Debt / EBITDA	0.44
Debt / FCF	0.51
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.86% and return on invested capital (ROIC) is 16.80%.

Return on Equity (ROE)	25.86%
Return on Assets (ROA)	14.02%
Return on Invested Capital (ROIC)	16.80%
Return on Capital Employed (ROCE)	23.58%
Revenue Per Employee	786,542
Profits Per Employee	214,080
Employee Count	9,980
Asset Turnover	0.68
Inventory Turnover	2.14

Taxes

In the past 12 months, ResMed has paid 422.27 million in taxes.

Income Tax	422.27M
Effective Tax Rate	16.50%

Stock Price Statistics

The stock price has increased by +28.88% in the last 52 weeks. The beta is 0.77, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+28.88%
50-Day Moving Average	39.86
200-Day Moving Average	37.74
Relative Strength Index (RSI)	65.07
Average Volume (20 Days)	1,070,259

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.04

Income Statement

In the last 12 months, ResMed had revenue of AUD 7.85 billion and earned 2.14 billion in profits. Earnings per share was 14.51.

Revenue	7.85B
Gross Profit	4.71B
Operating Income	2.57B
Pretax Income	2.56B
Net Income	2.14B
EBITDA	2.88B
EBIT	2.57B
Earnings Per Share (EPS)	14.51

Balance Sheet

The company has 1.84 billion in cash and 1.30 billion in debt, giving a net cash position of 545.50 million.

Cash & Cash Equivalents	1.84B
Total Debt	1.30B
Net Cash	545.50M
Net Cash Per Share	n/a
Equity (Book Value)	9.10B
Book Value Per Share	62.15
Working Capital	3.79B

Cash Flow

In the last 12 months, operating cash flow was 2.67 billion and capital expenditures -137.07 million, giving a free cash flow of 2.53 billion.

Operating Cash Flow	2.67B
Capital Expenditures	-137.07M
Free Cash Flow	2.53B
FCF Per Share	n/a

Margins

Gross margin is 59.99%, with operating and profit margins of 32.79% and 27.22%.

Gross Margin	59.99%
Operating Margin	32.79%
Pretax Margin	32.60%
Profit Margin	27.22%
EBITDA Margin	36.64%
EBIT Margin	32.79%
FCF Margin	32.29%

Dividends & Yields

This stock pays an annual dividend of 0.49, which amounts to a dividend yield of 1.13%.

Dividend Per Share	0.49
Dividend Yield	1.13%
Dividend Growth (YoY)	9.61%
Years of Dividend Growth	n/a
Payout Ratio	22.19%
Buyback Yield	0.14%
Shareholder Yield	1.27%
Earnings Yield	3.36%
FCF Yield	3.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.06 and a Piotroski F-Score of 7.

Altman Z-Score	12.06
Piotroski F-Score	7